Skip to Content
Merck
All Photos(1)

Documents

P-916

Supelco

Paroxetine maleate solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C19H20FNO3 · C4H4O4
CAS Number:
Molecular Weight:
445.44
EC Number:
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol (as free base)

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

OC(=O)\C=C/C(O)=O.Fc1ccc(cc1)[C@@H]2CCNC[C@H]2COc3ccc4OCOc4c3

InChI

1S/C19H20FNO3.C4H4O4/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18;5-3(6)1-2-4(7)8/h1-6,9,14,17,21H,7-8,10-12H2;1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-,17-;/m0./s1

InChI key

AEIUZSKXSWGSRU-QXGDPHCHSA-N

Gene Information

human ... SLC6A4(6532)

General description

Paroxetine, marketed under trade names such as Paxil® or Aropax, is an SSRI antidepressant used to treat many conditions in adults from major depression and obsessive-compulsive disorder to several anxiety disorders. Suitable uses for this certified solution standard include as a starting material for calibrators and controls in LC/MS or GC/MS paroxetine testing applications such as urine drug testing, prescription monitoring, clinical toxicology, or forensic analysis.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Paxil is a registered trademark of GlaxoSmithKline LLC
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 1

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

David Germann et al.
Profiles of drug substances, excipients, and related methodology, 38, 367-406 (2013-05-15)
Paroxetine hydrochloride (3S-trans)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-piperidine hydrochloride (or (-)-(3S,4R)-(4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)-phenoxy]methyl]piperidine hydrochloride), a phenylpiperidine derivative, is a selective serotonin reuptake inhibitor. Paroxetine is indicated for the treatment of depression, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, and social anxiety disorder. The physicochemical
Teaching an old drug new tricks: can paroxetine ease the burden of cardiovascular disease in diabetes?
Stephen B Wheatcroft
Diabetes, 62(3), 698-700 (2013-02-23)
Harry G Brittain
Profiles of drug substances, excipients, and related methodology, 38, 407-421 (2013-05-15)
The polymorphic (crystal systems for which a substance can exist in structures defined by different unit cells, and where each of the forms has the same elemental composition) and solvatomorphic (systems where the crystal structures of the substance are defined
Mohamed A El-Nabarawi et al.
International journal of pharmaceutics, 443(1-2), 307-317 (2013-01-23)
Paroxetine (PAX) is the most potent serotonin reuptake blocker antidepressant clinically available. This study is aimed to reduce the side effects accompanied with the initial high plasma concentration after oral administration of PAX and fluctuations in plasma levels and also
N Byatt et al.
Acta psychiatrica Scandinavica, 127(2), 94-114 (2012-12-18)
Conflicting data have led to controversy regarding antidepressant use during pregnancy. The objectives of this study are to i) review the risks of untreated depression and anxiety, ii) review the literature on risks of exposure to antidepressants during pregnancy, iii)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service